Candel Therapeutics, Inc.

NASDAQ (USD): Candel Therapeutics, Inc. (CADL)

Last Price

9.17

Today's Change

+0.37 (4.20%)

Day's Change

8.62 - 9.27

Trading Volume

1,889,934

Profile
CADL

Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Full Time Employees:  42 42

IPO Date:  2021-07-27 2021-07-27

CIK:  0001841387 0001841387

ISIN:  US1374041093 US1374041093

CUSIP:  137404109 137404109

Beta:  -0.87 -0.87

Last Dividend:  0.00 0.00

Dcf Diff:  8.69 8.69

Dcf:  0.44 0.44

Description

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Address

117 Kendrick Street,
Needham, MA 02494, US

617 916 5445

http://www.candeltx.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment